Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADAPTiON: Apixaban Dose Adjustment in Patient With Thrombocytopenia in ONcology
NCT06886516Phase 1Recruiting
- Start
- Feb 2025
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of apixaban in venous thromboembolism (VTE). Primary endpoint: Study Enrollment at 5 years. Started Feb 2025; status: recruiting.
02
Drugs
apixaban
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT06886516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06886516.